Amnio Technology
AZ - PhoenixBiotechnology
Focus: Amnio Technology develops and distributes amniotic tissue allografts, a regenerative medicine approach targeting chronic wounds and oncology indications. The company is an early-stage biotech founded in 2024 with a single Phase 2 program.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Amnio Technology
AI assessmentNot HiringNo open roles listed right now. Follow Amnio Technology to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Amniotic Tissue Allograft
Chronic Ulcer of Lower ExtremityClinical Trials (1)
NCT04667416Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities
Phase 2Help build intelligence for Amnio Technology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.